MONTREAL, QUEBEC--(CCNMatthews - Sept. 27, 2005) - Osta Biotechnologies Inc. (TSX VENTURE:OBI), today announced the publication of a landmark study in which its researchers have shown for the first time that the Parathyroid Hormone Related Peptide (PTHrP) derived from bone forming cells (osteoblasts) is a potent endogenous peptide for bone formation. It modifies the therapeutic efficacy of administered human PTH 1-34, a peptide similar in structure to Forteo, the only bone anabolic agent approved by the FDA currently on the market for the treatment of osteoporosis. The article entitled “Osteoblast-derived PTHrP is a Potent Endogenous Bone Anabolic Agent That Modifies the Therapeutic Efficacy of Administered PTH 1-34" is published in the online edition of The Journal of Clinical Investigation (JCI) at www.jci.org.
